Evidence map›Paper›PMID 32899818›Full record

ArticleCancers2020

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.

Sabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, Sven Mahner, Ignace Vergote, Liselore Loverix, Elena Braicu, Jalid Sehouli, Nicole Concin, Rainer Kimmig and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Explaining multivariate molecular diagnostic tests via Shapley values.BMC medical informatics and decision making · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sabine Kasimir-BauerDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45147 Essen, Germany.ORCID 0000-0002-8081-1799
Joanna RoderBiodesix, 2970 Wilderness Place #100, Boulder, CO 80301, USA.ORCID 0000-0001-8136-6167
Eva ObermayrDepartment of Obstetrics and Gynecology, Medical University of Vienna, Molecular Oncology Group, Gynecologic Cancer Unit, Comprehensive Cancer Center, 1090 Vienna, Austria.ORCID 0000-0001-6324-2961
Sven MahnerDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Ignace VergoteDepartment of Gynecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, B-3000 Leuven, Belgium.
Liselore LoverixDepartment of Gynecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, B-3000 Leuven, Belgium.ORCID 0000-0002-4741-6519
Elena BraicuDepartment of Gynecology, Charité University Medicine, Campus Virchow, 13353 Berlin, Germany.
Jalid SehouliDepartment of Gynecology, Charité University Medicine, Campus Virchow, 13353 Berlin, Germany.
Nicole ConcinDepartment of Gynecology and Obstetrics, Innsbruck Medical University, 6020 Innsbruck, Austria.
Rainer KimmigDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45147 Essen, Germany.
Lelia NetBiodesix, 2970 Wilderness Place #100, Boulder, CO 80301, USA.
Heinrich RoderBiodesix, 2970 Wilderness Place #100, Boulder, CO 80301, USA.
Robert ZeillingerDepartment of Obstetrics and Gynecology, Medical University of Vienna, Molecular Oncology Group, Gynecologic Cancer Unit, Comprehensive Cancer Center, 1090 Vienna, Austria.
Stefanie AustDepartment of Obstetrics and Gynecology, Medical University of Vienna, Molecular Oncology Group, Gynecologic Cancer Unit, Comprehensive Cancer Center, 1090 Vienna, Austria.
On Behalf Of The Ovcad Ovarian Cancer Diagnosis Initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass-spectrometry-based analyses have identified a variety of candidate protein biomarkers that might be crucial for epithelial ovarian cancer (EOC) development and therapy response. Comprehensive validation studies of the biological and clinical implications of proteomics are needed to advance them toward clinical use. Using the Deep MALDI method of mass spectrometry, we developed and independently validated (development cohort:

Indexed as

mass spectrometryovarian cancerproteomicssurvival

Identifiers

PMID32899818
PMCPMC7564837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.